Living Tumor Biopsies to Interrogate Immune Function and Response to Therapy

活体肿瘤活检以询问免疫功能和对治疗的反应

• 批准号: 9135274
• 负责人: MATTHEW F KRUMMEL
• 金额: $ 19.73万
• 依托单位: UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
• 依托单位国家: 美国
• 财政年份: 2015
• 资助国家: 美国
• 起止时间: 2015-09-01 至 2018-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9135274
• 关键词: Antibody Therapy; Beds; Behavior; Biological Assay; Biopsy; Biopsy Specimen; Breast; Color; Combined Modality Therapy; Complex; Development; Diagnostic; Diagnostics Research; Dose; Formalin; Future; Glean; Health; Human; ITGAM gene; Image; Image Analysis; Immune; Immune response; Immune system; In Situ; Individual; Life; Lung; Malignant Neoplasms; Measures; Medicine; Methods; Mus; Myelogenous; Nature; Operative Surgical Procedures; Pathology; Patient Rights; Patients; Pattern; Pharmaceutical Preparations; Plant Roots; Population; Preparation; Process; Punch Biopsy; Reader; Reagent; Resistance; Route; Sampling; Selection for Treatments; Series; Skin; Slice; Staging; Staining method; Stains; Stream; T cell response; T-Lymphocyte; Technology; Testing; Therapeutic; Time; Tissues; Variant; Work; blind; cell motility; cohort; experience; field study; human disease; immune function; innovation; mouse model; novel; novel therapeutics; outcome forecast; predicting response; research study; responders and non-responders; response; sample fixation; spatiotemporal; therapeutic development; tumor; tumor microenvironment; two-photon

 DESCRIPTION (provided by applicant): Treating the immune response within tumors is a major focus of new therapeutic development. For emerging therapies, there are clear responders and non-responders and at present, we are blind to knowing in how many ways the immune system is deficient. We are also unable to know which of the current or emerging therapies will work for a given patient. The current best-approach is to put each patient through a sequence of therapies before (hopefully) hitting upon one that works. In the future, we believe we will be able to tap the wealth of information that is contained in the just-excised biopsy of each patient. Each biopsy contains significantly more information than we currently glean in the form of the spatiotemporal cellular interactions that are taking place therein. Many immune activities continue to occur when biopsies are collected, maintained and imaged under appropriate conditions. We hypothesize that it is possible to study the functionality of the human tumor microenvironment `live' by the development of standard practices for `live biopsy'. If we are right, patient samples can be both characterized overall but also used as a test-bed for single or combinations of therapies to determine the most likely one to induce tumor rejection. Rare, small and information-rich human biospecimens will be directly and reproducibly studied and will be critical in next-gen discovery and diagnostic platforms. This study will define a serie of parameters by which biopsy samples can enter this important discovery stream.

 描述（由适用提供）：治疗肿瘤内的免疫响应是新治疗发育的主要重点。对于新兴疗法，有明显的反应者和非反应者，目前，我们盲目地知道免疫系统是确定性的。我们也无法知道哪种当前或新兴疗法对给定患者有效。目前的最佳选择是在（希望）击中有效的疗法之前，让每个患者通过一系列疗法。将来，我们相信我们将能够利用每个患者刚刚进行的活检中包含的大量信息。每个活检的信息都比我们目前以空间颞细胞相互作用的形式收集到的信息要多得多。当在适当条件下收集，维护和成像活检时，继续进行许多免疫活动。我们假设可以通过开发“活检”标准实践来研究人类肿瘤微环境“ Live”的功能。如果我们是对的，则可以将患者样本整体表征，也可以用作单一或疗法组合的测试床，以确定最有可能诱导肿瘤排斥的方法。稀有，小型和信息丰富的人类生物测量将直接和重复研究，并且在下一代发现和诊断平台中至关重要。这项研究将定义一系列参数，通过这些参数，活检样本可以进入这一重要发现流。